PL EN


Preferences help
enabled [disable] Abstract
Number of results
2017 | 64 | 3 | 519-525
Article title

Fatty acid amide hydrolase (FAAH) inhibitor PF-3845 reduces viability, migration and invasiveness of human colon adenocarcinoma Colo-205 cell line: an in vitro study

Content
Title variants
Languages of publication
EN
Abstracts
EN
Earlier reports suggest that the endocannabinoids may play a role of endogenous tumor growth modulators. In this study, we investigated whether inhibition of the enzymes involved in the synthesis and degradation of endocannabinoids may reduce colorectal cancer cell invasion and migration. The human colon adenocarcinoma Colo-205 cells were incubated with PF-3845, JZL-184 and RHC-80267 (fatty acid amide hydrolase (FAAH), mono- (MAGL) and diacylglycerol lipase (DAGL) inhibitors, respectively) for 48 h. The MTT colorimetric assay was performed to quantify cell viability. Next, Colo-205 cells were incubated with PF-3845 alone or with PF-3845 together with selected antagonists: AM 251, AM 630, SB 366791, RN 1734 and G-15 (CB1, CB2, TRPV1, TRPV4 and GPR30 antagonists, respectively). Western blot assay was applied to identify the changes in CB1 and CB2 receptor expression. Migration and invasion assays were employed to characterize the effect of PF-3845 on colorectal cancer cell invasion. We found that of all the inhibitors used, the FAAH inhibitor PF-3845 reduced the Colo-205 cell line viability the most effectively (IC50=52.55 μM). We also showed that the effect of decreased cell viability was enhanced when Colo-205 cells were incubated with PF-3845 and RN-1734, a TRPV4 antagonist (IC50=30.54 μM). Western blot assay revealed significantly decreased CB1 receptor expression levels, while CB2 expression was increased in response to PF-3845 when compared to control. Furthermore, PF-3845 inhibited migration and invasion of Colo-205 cell line. These results suggest that pharmacological inhibition of FAAH and consequent enhancement of the endocannabinoid levels may reduce the colorectal cancer growth and progression.
Publisher

Year
Volume
64
Issue
3
Pages
519-525
Physical description
Dates
published
2017
received
2017-02-01
revised
2017-03-14
accepted
2017-04-14
(unknown)
2017-08-30
Contributors
  • Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Łódź, Poland
  • Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Faculty of Pharmacy, Medical University of Lodz, Łódź, Poland
  • Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Łódź, Poland
  • Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Łódź, Poland
author
  • Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Łódź, Poland
References
  • Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, Weerapana E, Sadagopan N, Liimatta M, Smith SE, Lazerwith S, Stiff C, Kamtekar S, Bhattacharya K, Zhang Y, Swaney S, Van Becelaere K, Stevens RC, Cravatt BF (2009) Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 16: 411-420. doi: 10.1016/j.chembiol.2009.02.013.
  • Alberich Jordà M, Rayman N, Tas M, Verbakel SE, Battista N, van Lom K, Löwenberg B, Maccarrone M, Delwel R (2004) The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. Blood 104: 526-534. doi: 10.1182/blood-2003-12-4357.
  • Bifulco M, Laezza C, Pisanti S, Gazzerro P (2006) Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 148: 123-135. doi: 10.1038/sj.bjp.0706632.
  • Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G, DI Marzo V (2004) A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 18: 1606-608. doi: 10.1096/fj.04-1754fje.
  • Björklund E, Larsson TN, Jacobsson SO, Fowler CJ (2014) Ketoconazole inhibits the cellular uptake of anandamide via inhibition of FAAH at pharmacologically relevant concentrations. PLoS One 9: e87542. doi: 10.1371/journal.pone.0087542.
  • Caffarel MM, Sarrio D, Palacios J, Guzman M, Sanchez C (2006) Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 66: 6615-6621. doi: 10.1158/0008-5472.CAN-05-4566.
  • Chicca A, Marazzi J, Nicolussi S, Gertsch J (2012) Evidence for bidirectional endocannabinoid transport across cell membranes. J Biol Chem 287: 34660-34682. doi: 10.1074/jbc.M112.373241.
  • Cianchi F, Papucci L, Schiavone N, Lulli M, Magnelli L, Vinci MC, Messerini L, Manera C, Ronconi E, Romagnani P, Donnini M, Perigli G, Trallori G, Tanganelli E, Capaccioli S, Masini E (2008) Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells. Clin Cancer Res 14: 7691-7700. doi: 10.1158/1078-0432.CCR-08-0799.
  • Cipriano M, Haggstrom J, Hammarsten P, Fowler CJ (2013) Association between cannabinoid CB₁ receptor expression and Akt signalling in prostate cancer. PLoS One 8: e65798. doi: 10.1371/journal.pone.0065798.
  • Cudaback E, Marrs W, Moeller T, Stella N (2010) The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas. PLoS One 5: e8702. doi: 10.1371/journal.pone.0008702.
  • Day TA, Rakhshan F, Deutsch DG, Barker EL (2001) Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol Pharmacol 59: 1369-1375.
  • De Lago E, Gustafsson SB, Fernandez-Ruiz J, Nilsson J, Jacobsson SO, Fowler CJ (2006) Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. J Neurochem 99: 677-688. doi: 10.1111/j.1471-4159.2006.04104.x.
  • Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949.
  • Ek S, Hogerkorp CM, Dictor M, Ehinger M, Borrebaeck CA (2002) Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res 62: 4398-4405.
  • Endsley MP, Aggarwal N, Isbell MA, Wheelock CE, Hammock BD, Falck JR, Campbell WB, Nithipatikom K (2007) Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: Location, hydrolysis and 12-lipoxygenase metabolism. Int J Cancer 121: 984-991. doi: 10.1002/ijc.22761.
  • Fowler CJ (2013) Transport of endocannabinoids across the plasma membrane and within the cell. FEBS J 280: 1895-1904. doi: 10.1111/febs.12212.
  • Gerard CM, Mollereau C, Vassart G, Parmentier M (1991) Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 279: 129-134.
  • Gustafsson SB, Palmqvist R, Henriksson ML, Dahlin AM, Edin S, Jacobsson SO, Öberg Å, Fowler CJ (2011) High tumour cannabinoid CB1 receptor immunoreactivity negatively impacts disease-specific survival in stage II microsatellite stable colorectal cancer. PLoS One 6: e23003. doi: 10.1371/journal.pone.0023003.
  • Hansen MB, Nielsen SE, Berg K (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-210.
  • Hofmann NA, Barth S, Waldeck-Weiermair M, Klec C, Strunk D, Malli R, Graier WF (2014) TRPV1 mediates cellular uptake of anandamide and thus promotes endothelial cell proliferation and network-formation. Biol Open 3: 1164-1172. doi: 10.1242/bio.20149571.
  • Islam TC, Asplund AC, Lindvall JM, Nygren L, Liden J, Kimby E, Christensson B, Smith CI, Sander B (2003) High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma. Leukemia 17: 1880-1890. doi: 10.1038/sj.leu.2403057.
  • Jung CK, Kang WK, Park JM, Ahn HJ, Kim SW, Taek Oh S, Choi KY (2013) Expression of the cannabinoid type I receptor and prognosis following surgery in colorectal cancer. Oncol Lett 5: 870-876. doi: 10.3892/ol.2012.1081.
  • Kelly H, Goldberg RM (2005) Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 23: 4553-4560. doi: 10.1200/JCO.2005.17.749.
  • Laezza C, Pisanti S, Malfitano AM, Bifulco M (2008) The anandamide analog, Met-F-AEA, controls human breast cancer cell migration via the RHOA/RHO kinase signaling pathway. Endocr Relat Cancer 15: 965-974. doi: 10.1677/ERC-08-0030.
  • Lewandowska U, Szewczyk K, Owczarek K, Hrabec Z, Podsędek A, Koziołkiewicz M, Hrabec E (2013) Flavanols from Japanese quince (Chaenomeles japonica) fruit inhibit human prostate and breast cancer cell line invasiveness and cause favorable changes in Bax/Bcl-2 mRNA ratio. Nutr Cancer 65: 273-285. doi: 10.1080/01635581.2013.749292.
  • Liu J, Wang L, Harvey-White J, Huang BX, Kim HY, Luquet S, Palmiter RD, Krystal G, Rai R, Mahadevan A, Razdan RK, Kunos G (2008) Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 54: 1-7. doi: 10.1016/j.neuropharm.2007.05.020.
  • Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D (2004) Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308: 838-845. doi: 10.1124/jpet.103.061002.
  • Matas D, Juknat A, Pietr M, Klin Y, Vogel Z (2007) Anandamide protects from low serum-induced apoptosis via its degradation to ethanolamine. J Biol Chem 282: 7885-7892. doi: 10.1074/jbc.M608646200.
  • Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564. doi: 10.1038/346561a0.
  • Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90.
  • Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65. doi: 10.1038/365061a0.
  • Nithipatikom K, Endsley MP, Isbell MA, Falck JR, Iwamoto Y, Hillard CJ, Campbell WB (2004) 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer invasion. Cancer Res 64: 8826-8830. doi: 10.1158/0008-5472.CAN-04-3136.
  • Pertwee RG (2006) The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes Lond 30 (Suppl 1): S13-S18. doi: 10.1038/sj.ijo.0803272.
  • Ralevic V, Kendall DA, Jerman JC, Middlemiss DN, Smart D (2001) Cannabinoid activation of recombinant and endogenous vanilloid receptors. Eur J Pharmacol 424: 211-219.
  • Ranger JJ, Levy DE, Shahalizadeh S, Hallett M, Muller WJ (2009) Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. Cancer Res 69: 6823-6830. doi: 10.1158/0008-5472.CAN-09-1684.
  • Reggio PH, Traore H (2000) Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase. Chem Phys Lipids 108: 15-35.
  • Rudolph MI, Boza Y, Yefi R, Luza S, Andrews E, Penissi A, Garrido P, Rojas IG (2008) The influence of mast cell mediators on migration of SW756 cervical carcinoma cells. J Pharmacol Sci 106: 208-218.
  • Steward BW, Wild CP (2014) World Cancer Report. World Health Organisation.
  • Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D (2005) Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol 144: 1032-1036. doi: 10.1038/sj.bjp.0706134.
  • Wang D, Wang H, Ning W, Backlund MG, Dey SK, DuBois RN (2008) Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res 68: 6468-6476. doi: 10.1158/0008-5472.CAN-08-0896.
  • Ye L, Zhang B, Seviour EG, Tao KX, Liu XH, Ling Y, Chen JY, Wang GB (2011) Monoacylglycerol lipase (MAGL) knockdown inhibits tumor cells growth in colorectal cancer. Cancer Lett 307: 6-17. doi: 10.1016/j.canlet.2011.03.007.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv64p519kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.